Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Rosell

Showing results (141-150 of 565) with videos related to

Pageof 57
Sort By:
Expert Opinion on Investigational Drugs|February 19, 2024
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusionsRafael Rosell, Carlos Pedraz-Valdunciel, Anisha Jain, et al.
Expert Review of Clinical Pharmacology|July 30, 2019
Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancerMariacarmela Santarpia, Jessica Menis, Imane Chaib, et al.
Translational Lung Cancer Research|March 26, 2015
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitorsJosé Miguel Sánchez-Torres, Santiago Viteri, Miguel Angel Molina, et al.
Translational Lung Cancer Research|January 23, 2016
Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancerSantiago Viteri, María González-Cao, Feliciano Barrón, et al.
Current Opinion in Oncology|December 2, 2009
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancerRafael Rosell, Santiago Viteri, Miguel Angel Molina, et al.
Discovery Medicine|December 31, 2009
Screening for EGFR mutations in lung cancerMiguel A Molina-Vila, Jordi Bertran-Alamillo, Clara Mayo, et al.
Translational Lung Cancer Research|March 26, 2015
Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangementsCristina Teixidó, Niki Karachaliou, Vicente Peg, et al.
Translational Cancer Research|February 4, 2022
EGFR first- and second-generation TKIs-there is still place for them in <i>EGFR</i>-mutant NSCLC patientsNiki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, et al.
Medical Oncology (Northwood, London, England)|September 7, 2022
Anti-EGF nanobodies enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer (NSCLC) cellular modelsSalvador Guardiola, Macarena Sánchez-Navarro, Rafael Rosell, et al.
Cancer Biology & Medicine|October 22, 2015
Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapyCristina Teixidó, Niki Karachaliou, Maria González-Cao, et al.
Pageof 57

Showing results (141-150 of 565) with videos related to

Sort By:
Pageof 57
Expert Opinion on Investigational Drugs|February 19, 2024
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusionsRafael Rosell, Carlos Pedraz-Valdunciel, Anisha Jain, et al.
Expert Review of Clinical Pharmacology|July 30, 2019
Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancerMariacarmela Santarpia, Jessica Menis, Imane Chaib, et al.
Translational Lung Cancer Research|March 26, 2015
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitorsJosé Miguel Sánchez-Torres, Santiago Viteri, Miguel Angel Molina, et al.
Translational Lung Cancer Research|January 23, 2016
Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancerSantiago Viteri, María González-Cao, Feliciano Barrón, et al.
Current Opinion in Oncology|December 2, 2009
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancerRafael Rosell, Santiago Viteri, Miguel Angel Molina, et al.
Discovery Medicine|December 31, 2009
Screening for EGFR mutations in lung cancerMiguel A Molina-Vila, Jordi Bertran-Alamillo, Clara Mayo, et al.
Translational Lung Cancer Research|March 26, 2015
Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangementsCristina Teixidó, Niki Karachaliou, Vicente Peg, et al.
Translational Cancer Research|February 4, 2022
EGFR first- and second-generation TKIs-there is still place for them in <i>EGFR</i>-mutant NSCLC patientsNiki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, et al.
Medical Oncology (Northwood, London, England)|September 7, 2022
Anti-EGF nanobodies enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer (NSCLC) cellular modelsSalvador Guardiola, Macarena Sánchez-Navarro, Rafael Rosell, et al.
Cancer Biology & Medicine|October 22, 2015
Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapyCristina Teixidó, Niki Karachaliou, Maria González-Cao, et al.
Pageof 57